34 results about "Multidrug resistant bacteria" patented technology

The present invention relates to a convenient, flexible and cost-efficient technology for detection and resistance-profiling of bacteria, enabling effective, evidence-based treatment of infections. The invention provides methods and modular kits for the rapid and direct detection of beta-lactam resistant bacteria in a test sample, and optionally for susceptibility profiling of the bacteria, by directly determining hydrolysis product / s of beta-lactam antibiotic substrates in the tested sample. The invention also provides methods and modular kits for the rapid and direct detection of the presence of multidrug resistant bacteria in a test sample.

The invention belongs to the field of medicinal chemistry and discloses a pleuromutilin derivative with a 2-amino phenyl mercaptan side chain and a preparing method and application of the pleuromutilin derivative. The compound has the structures shown in formula 2 and formula 3, wherein R1, R2 and R3 are respectively and independently selected from the hydrogen atom, the hydroxyl, the amino, the sulfydryl, the hydroxymethyl, the amine methyl, the nitro, the halogen, the trihalogenated methyl, the methyl, the natural amino acid acylamino and the C1-6 alkoxy. The pleuromutilin derivative with the 2-amino phenyl mercaptan side chain has good activity for inhibiting the drug resistant staphylococcus aureus and the mycoplasma and is particularly suitable for serving as a novel antibacterial medicine for preventing infectious diseases caused by the human or animal mycoplasma or drug resistant staphylococcus aureus or multidrug resistant bacteria.

The invention provides a group of peptide nucleic acid-cell penetrating peptide antisense antibacterial sequences taking bacterial gene rpoD as a target. The cell penetrating peptide-mediated antibacterial RNA polymerase sigma 70 factor gene rpoD which is antisense nucleic acid of a specificity target can selectively inhibit the expression of in-vivo ropD genes of Gram-negative bacterium (containing sensitive and multidrug resisting clinical pathogenicity Escherichia coli, salmonellatyphimurium, Klebsiella pneumoniae and pseudomonas aeruginosa) or gram-positive bacterium (containing sensitiveand multidrug resisting staphylococcus aureus) and further inhibit bacteria growth and reproduction, thus having the advantages of good antibacterial effect, low toxicity, good stability and better tolerance. The invention also discloses a chemical preparation method of a peptide nucleic acid-cell penetrating peptide solid phase. The antibacterial peptide synthesized in the invention can be used for preparing multidrug-resistant bacteria infection proofing antisense drugs and has the potency of being developed into a broad-spectrum antisense antibacterial agent which is expressed by efficiently transferred and peculiarly blocked bacterium disease-causing genes.

The invention discloses 3-nitro-2H-chromene compounds, a preparation method and application thereof. The 3-nitro-2H-chromene compounds have a novel antimicrobial parent nucleus structure, are prepared by reacting salicylaldehyde or substituted salicylaldehyde, n-Bu2NH, phthalic anhydride and 2-nitroethanol, and can be used for preparing medicaments for treating infectious diseases, particularly can be used for preparing medicaments for treating infectious diseases caused by multidrug-resistant bacteria.

The present invention relates to uses of Macrolactin A produced by Bacillus polyfermenticus KJS-2 (KCCM 10769P), which is a new bacillus strain, as an antibiotic. Macrolactin A of the present invention, which is produced by Bacillus polyfermenticus KJS-2, shows a broad spectrum of antibiotic activity against a variety of microorganisms and fungi, and is proved to be very efficient for the inhibition of particularly vancomycin-resistant enterococci (VRE) and methicillin-resistant Staphylococcus Aureus (MRSA) that are multidrug-resistant bacteria. The antibiotic Macrolactin A produced by Bacillus polyfermenticus KJS-2, can be used as an excellent antibiotic against vancomycin-resistant enterococci (VRE) and methicillin-resistant Staphylococcus Aureus (MRSA), and thus the present invention is a very useful invention for medical industry.

The invention belongs to the technical field of preparation of nano-selenium, and discloses functional nano-selenium and preparation method thereof as well as application of functional nano-selenium in preparation of anti-bacteria and sterilization drugs. The functional nano-selenium is at least one of nano-selenium modified by quercetin, nano-selenium modified by acetylcholine chloride and nano-selenium modified by quercetin-acetylcholine chloride. The functional nano-selenium has the activity for killing bacteria and multidrug resistant bacteria, also has the biological activity for inhibiting the growth of bacteria and multidrug resistant bacteria, and is suitable for preparing drugs for inhibiting the growth of bacteria and multidrug resistant bacteria and sterilization drugs. The functional nano-selenium is simple in preparation method, can be obtained through in-situ reduction modification, and can be directly stored and used. The functional nano-selenium is modified through various functions, so that the targeting property of the functional nano-selenium is improved, the transportation and transmembrane absorption of the functional nano-selenium in a bacteria cell membrane are improved, the medicine intake of bacteria can be increased, and the discharge is reduced, so that the fact that drugs in bacteria cells are kept at a higher level is ensured.

To provide a multidrug-resistant Gram positive bacteria antibacterial agent containing as an active ingredient a novel component to which multidrug-resistant bacteria are not resistant, and an external agent containing the same. The multidrug resistant Gram-positive bacteria antibacterial agent according to the present invention contains an amphipathic compound having an HLB value of greater than 9.5 and 20 or less and an acyl group as an active ingredient. The external agent according to the present invention contains the multidrug resistant Gram-positive bacteria antibacterial agent.

The present invention relates to an antimicrobial peptide having an improved antibacterial effect through glutamic acid substitution and, more specifically, to a use of the antimicrobial peptide as an active ingredient in an antibacterial pharmaceutical composition, a food additive, a feed additive, an antiseptic composition, and an antibacterial quasi-drug composition. Not only does the antimicrobial peptide of the present invention exhibit significant antibacterial activity against gram-negative bacteria, but it also exhibits a significant synergistic effect when combinedly treated with antibiotics which have strong antibacterial activity only against gram-positive bacteria and has no or low antibacterial activity against gram-negative bacteria, thereby exhibiting excellent antibacterial effects on gram-positive bacteria, E. coli and Acinetobacter bacteria among gram-negative bacteria, and antibiotic-resistant strains thereof.

The invention provides an amino sugar modified antibacterial gold nanoparticle and a preparation method thereof, and applications. The prepared antibacterial gold nanoparticle has an excellent antibacterial property, and can resist multidrug resistant bacteria; and the antibacterial gold nanoparticle is good in biocompatibility and low in toxicity to body cells. The antibacterial gold nanoparticlecan be used for clinical wound management, operations to prevent organs from adhering, beauty treatment, and various wound infections such as burn, scald and bedsore infections, so that the antibacterial gold nanoparticle is an extremely excellent medical antibacterial material.

The invention belongs to the field of biotechnologies, and provides a method for evolving the host specificity of a bacteriophage by the aid of a springboard host, the obtained springboard host and the obtained bacteriophage. The method, the springboard host and the bacteriophage have the advantages that lipopolysaccharide structures in bacteriophage hosts start to be transformed from known bacteriophages with clear genetic backgrounds by the aid of ideas and means of evolutionary biology and synthetic biology to obtain the springboard host, the springboard host can be infected by bacteriophages to obtain bacteriophages with variant receptor binding proteins, and the host specificity of the bacteriophages is changed, so that new host bacteria can be recognized and infected by the bacteriophages; as shown by experiments, the obtained bacteriophage can resist Gram-negative bacteria and multidrug-resistant bacteria, plaque can be generated, growth can be inhibited, and the bacteriophage has the potential of supplement and reinforcement effects for bacteria infection treatment by the aid of antibiotics.

The invention provides application of 3-mercaptopropionic acid amide compounds with the following general formula (I) in medicine which restrains the activity of multidrug-resistant bacteria through restraining the activity of NDM-1, wherein R1 is selected from a formula and R2 is selected from a C1-C4 alkyl group.

A novel antibacterial agent for Gram-positive bacteria which disregards the drug-resistant mechanisms of bacteria is disclosed. The antibacterial agent contains as an effective ingredient particles having a particle diameter of not more than 5 μm, which particles are adhesive to cell wall of Gram-positive bacteria and not adhesive to mammalian cell membrane and substantially do not contain an active antibacterial ingredient effective against Gram-positive bacteria. By the antibacterial agent according to the present invention, the growth of the multidrug-resistant Gram-positive bacteria such as MRSA and VRE can be inhibited, as well as the occurrence of novel multidrug-resistant bacteria, which is a big problem in use of antibiotics, can be avoided.

Disclosed are methods of treating bacterial infections including those caused by multidrug resistant bacteria using polyamine efflux pump inhibiting compounds, including for example N-benzylated polyazaalkanes, N-benzylated polyaminoalkanes, or mixed N-benzylated poly(aza / amino)alkanes, optionally in combination with other drugs such as antibiotics, as well as pharmaceutical compositions thereof.

The present invention relates to uses of Macrolactin A produced by Bacillus polyfermenticus KJS-2 (KCCM 10769P), which is a new bacillus strain, as an antibiotic. Macrolactin A of the present invention, which is produced by Bacillus polyfermenticus KJS-2, shows a broad spectrum of antibiotic activity against a variety of microorganisms and fungi, and is proved to be very efficient for the inhibition of particularly vancomycin-resistant enterococci (VRE) and methicillin-resistant Staphylococcus Aureus (MRSA) that are multidrug-resistant bacteria. The antibiotic Macrolactin A produced by Bacillus polyfermenticus KJS-2, can be used as an excellent antibiotic against vancomycin-resistant enterococci (VRE) and methicillin-resistant Staphylococcus Aureus (MRSA), and thus the present invention is a very useful invention for medical industry.

The invention provides a method of overcoming resistance to at least one antibiotic in a multidrug resistant bacterium, said method comprising contacting said bacterium with an alginate oligomer together with the antibiotic. The multidrug resistant bacterium may be on an animate or inanimate surface and both medical and non-medical uses and methods are provided. In one aspect the invention provides an alginate oligomer for use together with at least one antibiotic in treating a subject infected, suspected to be infected, or at risk of infection, with a multidrug resistant bacterium to overcome resistance to the antibiotic in said multidrug resistant bacterium. In another aspect the method can be used to combat contamination of a site with multidrug resistant bacteria, e.g. for disinfection and cleaning purposes.

Disclosed are methods of treating bacterial infections including those caused by multidrug resistant bacteria using polyamine efflux pump inhibiting compounds, including for example N-benzylated polyazaalkanes, N-benzylated polyaminoalkanes, or mixed N-benzylated poly(aza / amino)alkanes, optionally in combination with other drugs such as antibiotics, as well as pharmaceutical compositions thereof.

The invention provides a multifunctional cloth. By using the ionization effect of low-level microscale radiation which is not apparently different from that from natural ores in BG, that is, the radiation harmless to the human, under the condition of needing no artificial energy, light sources, etc., the multifunctional cloth has the effective antibacterial effect and the deodorizing effect constantly in 24 hours, is suitable for indoor application, and in excellent is infection prevention and deodorization. Ceramics containing uranium-series nuclides or thorium-series nuclides are fixed on a grey cloth to form the multifunctional cloth with excellent infection prevention and deodorization. The multifunctional cloth is characterized in that, by the ionization effect of the ceramics, when bacteria evaluated by the JIS-L-I902 bacteria transferring method is reduced, the multidrug resistant bacteria MRSA, the pneumobacillus and the staphylococcus aureus are all more than 0.0, and the deodorization efficiency of ammonium odour obtained by the deodorization experiment according to the JIS-L-2017-103 method is higher than 90%.

The invention discloses a disubstituted bicyclic derivative and application thereof as an efflux pump inhibitor to anti-microbial. It is proved by experiments that the disubstituted bicyclic derivative has a good inhibition function on multidrug-resistant bacteria carrying an AcrB efflux pump and can effectively recover or enhance antibacterial efficiency of existing antibiotics. The chemical structural formula of the disubstituted bicyclic derivative is as shown in a formula (I) (the formula can be seen in specification), and R1, R2, X, Y, Z and W are as defined in the specification.

The invention relates to the technical field of medicines, in particular to an experiment method for multidrug resistant bacterial infection of burn wounds. The experiment method comprises the following steps of A, performing target bacteria action research on a functional graphene nanometer composite modified with a free radical initiating agent under in vivo and in vitro conditions; B, under thein vivo and in vitro conditions, performing photo-irradiation induced target antibiotic action research on the functional graphene nanometer composite modified with the free radical initiating agentunder in vivo and in vitro conditions; C, performing research of influence of the functional graphene nanometer composite modified with the free radical initiating agent on multidrug resistant bacterial infection wound healing and an action mechanism of the functional graphene nanometer composite modified with the free radical initiating agent; and D, performing research on the biological safety of the functional graphene nanometer composite modified with the free radical initiating agent. Under complex conditions, the invention provides more selections for an application of photodynamic therapy and photothermal therapy under complex conditions, provides a new treatment direction and strategy for multidrug resistant bacterial infection of burn wounds, and is favorable for further exploration of a new multi-functional nanometer platform for multidrug resistant bacteria treatment.

Disclosed is a novel antimicrobial agent for Gram-positive bacteria extending beyond the mechanism of bacterial drug resistance. The antimicrobial agent contains, as active ingredients, particles which adhere to a Gram-positive bacterial cell wall and do not adhere to a mammalian cell membrane, have a particle diameter of 5 [mu]m or less, and practically do not contain an antimicrobially active component against Gram-positive bacteria. According to the antimicrobial agent of the invention, antimicrobial effect also on Gram-positive bacteria showing multidrug resistance typified by MRSA and VRE can be achieved. Further, the emergence of new multidrug resistant bacteria which becomes a major problem in the use of an antibiotic can be avoided.

The invention relates to the field of medicinal chemistry, and particularly relates to a five-membered heterocyclic dicarbonyl derivative (I) and applications thereof for resisting multidrug-resistant bacteria. Proved by pharmacological tests, the compound is jointly combined with antibiotics, thus having better inhibition effect on the multidrug-resistant bacteria.

The invention provides a method of overcoming resistance to at least one antibiotic in a multidrug resistant bacterium, said method comprising contacting said bacterium with an alginate oligomer together with the antibiotic. The multidrug resistant bacterium may be on an animate or inanimate surface and both medical and non-medical uses and methods are provided. In one aspect the invention provides an alginate oligomer for use together with at least one antibiotic in treating a subject infected, suspected to be infected, or at risk of infection, with a multidrug resistant bacterium to overcome resistance to the antibiotic in said multidrug resistant bacterium. In another aspect the method can be used to combat contamination of a site with multidrug resistant bacteria, e.g. for disinfection and cleaning purposes.

Disclosed are a benzoxazine oxazolidinone compound shown by a general formula (I), an optical isomer thereof or a pharmaceutically acceptable salt thereof, a preparation method thereof, and an application thereof in preparing a drug for treating an infectious disease and in particular, an infectious disease caused by multidrug resistant bacteria.

The invention relates to an application of a tetraphenyl ethylene derivative in preparation of an antibacterial agent. The tetraphenyl ethylene derivative has a tetraphenyl ethylene structure with a substituent group on at least one benzene ring, can resist multidrug-resistant bacteria, especially can also resist planktonic bacteria and biofilm bacteria, can be used for effectively eliminating a biofilm, is low in cytotoxicity, has no hemolysis side effect, can be used for curing an animal model infected by common bacteria and multidrug-resistant bacteria and has a broad application prospect in the field of preparation of antibacterial agents.

The present invention provides pyrimidine-isoquinolin-quinone derivatives of formula I, their salts, isomers, pharmaceutically acceptable tautomers; pharmaceutical composition; preparation procedure; and their use in the treatment of bacterial and resistant bacterial diseases, such as methicillin-resistant Staphylococcus aureus (MRSA), intermediate vancomycin-resistant Staphylococcus aureus (VISA), vancomycin-resistant Staphylococcus aureus (VRSA), vancomycin-resistant Enterococcus spp. (VRE), Enterococcus faecalis, Emerging Staphylococcus aureus with resistance to linezolid and / or bacterial strains not susceptible to daptomycin.Where the radicals R1, R2, R3, R4 and R5 are as defined in the work specifications of the present invention.

The present invention relates to a novel metallo-beta-lactamase (MBL) inhibitor of formula I and an antibacterial composition comprising the same for use in the treatment of multidrug resistant bacteria. In particular, the present invention relates to 3, 5-dichlorophenylboronic acid, (4-(4-amino-3-chlorophenoxy)-3, 5-dichlorophenylboronic acid, and (3, 5-dichloro-4-(2-hydroxyethoxy) phenyl) boronic acid. The compounds of formula I according to the present invention have inhibitory activity against broad spectrum metallo-beta-lactamase. By administering the MBL inhibitor of the present invention together with a beta-lactam antibiotic agent, it is possible to protect the antibiotic agent from degradation by MBL produced by microorganisms. Therefore, the time and range of the antibacterial agent activity can be extended or expanded. Some bacteria that are resistant to antibacterial agents due to the presence of MBL can be controlled by the composition of the invention. Therefore, the invention can be used for treating or preventing infection of antibiotic-resistant bacteria.

The invention belongs to the technical field of preparation of nano-selenium, and discloses functional nano-selenium and preparation method thereof as well as application of functional nano-selenium in preparation of anti-bacteria and sterilization drugs. The functional nano-selenium is at least one of nano-selenium modified by quercetin, nano-selenium modified by acetylcholine chloride and nano-selenium modified by quercetin-acetylcholine chloride. The functional nano-selenium has the activity for killing bacteria and multidrug resistant bacteria, also has the biological activity for inhibiting the growth of bacteria and multidrug resistant bacteria, and is suitable for preparing drugs for inhibiting the growth of bacteria and multidrug resistant bacteria and sterilization drugs. The functional nano-selenium is simple in preparation method, can be obtained through in-situ reduction modification, and can be directly stored and used. The functional nano-selenium is modified through various functions, so that the targeting property of the functional nano-selenium is improved, the transportation and transmembrane absorption of the functional nano-selenium in a bacteria cell membrane are improved, the medicine intake of bacteria can be increased, and the discharge is reduced, so that the fact that drugs in bacteria cells are kept at a higher level is ensured.

A pleuromutilin derivative having a 2-amino phenyl mercaptan side chain as well as a preparation method and application thereof are provided. The derivative has a structure represented by formula 2 or formula 3, wherein, R1, R2 and R3 are each independently selected from a hydrogen atom, hydroxyl, amino, sulfydryl, hydroxymethyl, amine methyl, nitro, halogen, trihalogenated methyl, methyl, natural amino acid acylamino and C1-6 alkoxy. The plueuromutilin derivative in the disclosure has good activity of inhibiting drug-resistant staphylococcus aureus and mycoplasma, and is especially suitable for preventing and treating infectious diseases caused by human or animal mycoplasma or drug-resistant staphylococcus aureus or multidrug resistant bacteria as a novel antibacterial drug.